Short-term antibody response afer 1 dose of BNT162b2 vaccine in patients receiving hemodialysis
Short-term antibody response afer 1 dose of BNT162b2 vaccine in patients receiving hemodialysis
About this item
Full title
Short-term antibody response afer 1 dose of BNT162b2 vaccine in patients receiving hemodialysis
Author / Creator
Publisher
Canada
Journal title
Canadian Medical Association journal (CMAJ), 2021-05
Language
English
Formats
Publication information
Publisher
Canada
More information
Scope and Contents
Contents
Patients receiving in-centre hemodialysis are at high risk of exposure to SARS-CoV-2 and death if infected. One dose of the BNT162b2 SARS-CoV-2 vaccine is eficacious in the general population, but responses in patients receiving hemodialysis are uncertain.
We obtained serial plasma from patients receiving hemodialysis and health care worker cont...
Alternative Titles
Full title
Short-term antibody response afer 1 dose of BNT162b2 vaccine in patients receiving hemodialysis
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmed_primary_33980499
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmed_primary_33980499
Other Identifiers
E-ISSN
1488-2329
DOI
10.1503/cmaj.210673
